Table S1: List of 16 withdrawn analgesics that were marketed in both Europe and the USA

Product	Withdrawn in Europe	Reason for withdrawal in Europe	Withdrawn in USA	Reason for withdrawal in the USA	Action when the product was not withdrawn
Benoxaprofen	Yes	Liver toxicity	Yes	Liver toxicity	–
Bufexamac	Yes	Allergic reactions	No		New formulation marketed to reduce drug absorption
Buprenorphine	No		No		Uses restricted [in both cases]
Celecoxib	Yes	Myocardial infarction, stroke	No		"Black box" warning†
Co-proxamol	Yes	Drug abuse	Yes	Drug abuse	–
Diclofenac sodium*	Yes	Carcinogenicity	No		No change (evidence of carcinogenicity regarded as inconclusive)
Fenclozic acid	Yes	Liver toxicity	Yes	Liver toxicity	–
Fentanyl hydrochloride	Yes	Drug abuse	No		Re–formulated
Ketorolac	Yes	Gastrointestinal haemorrhage	No		"Black box" warning‡
Oxyphenbutazone	Yes	Bone marrow suppression	Yes	Bone marrow suppression	–
Pirprofen	Yes	Liver toxicity	Yes	Liver toxicity	–
Propyphenazone	Yes	Lyell's syndrome; bone marrow suppression	Yes	Lyell's syndrome; bone marrow suppression	–
Rofecoxib	Yes	Myocardial infarction	Yes	Myocardial infarction	–
Suprofen	Yes	Renal toxicity	Yes	Diminished sales	–
Valdecoxib	Yes	Cardiovascular and skin reactions	Yes	Cardiovascular and skin reactions	–
Zomepirac	Yes	Anaphylaxis	Yes	Anaphylaxis	–

*Refused registration because carcinogenicity testing in rats was inconclusive and involved the use of only one rodent species
†Consider alternative therapy; use lowest effective dose if appropriate (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108384.htm)
‡Contraindications: peptic ulcer, renal impairment, bleeding diathesis, following heart surgery (http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019645s016lbl.pdf)